Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD20 B-cell depletion in systemic sclerosis
NL-OMON24091Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Jan 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) (2 arms), sponsored by Roche. Primary endpoints: Treatment-related mortality, Treatment toxicity and 2 more. Planned start Jan 2009; status: not yet recruiting.
02
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON24091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24091.